18.12.2019 – 14:07Grünenthal GroupAveritas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral NeuropathyMorristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...more
20.02.2019 – 15:54AlvogenAlvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual FilmPine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths. The launch took ...more
14.11.2018 – 13:00Averitas PharmaAveritas Pharma commercializes Qutenza® in the USMorristown, New Jersey (ots) - Averitas Pharma, a recently acquired Grünenthal Group company, announced that it has taken over the US commercialization of Qutenza® (capsaicin) 8% patch on October 30, after the acquisition of the product by Grünenthal on the same day. Qutenza® is approved in the US for the management of neuropathic pain associated with postherpetic neuralgia. A single, 1-hour, localized treatment with ...more
